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To critically appraise, synthesise, and present the available evidence on the impact of pharmacists’ input on
the screening, prevention and management of metabolic syndrome (MetS).
Specific aims:
1-   To determine the types of pharmacist interventions reported in the studies.
2-   To describe the impact of the identified interventions as reported in the studies.
3-   To identify the facilitators and barriers to the effective implementation of pharmacist interventions in the
screening, prevention and management of MetS.
4-   To characterise the populations who could benefit most from the interventions.
 
Searches
A thorough search and appraisal of the current published literature regarding the impact of pharmacists’
interventions on the screening, prevention and management of MetS will be carried out. 
An exploratory search has indicated that the first relevant article was published in 2008, and hence, all
studies published from 2008 onwards in the English language will be included.
The search will be conducted electronically, using medical subject headings (MeSH), and will involve the
following databases; MEDLINE, CINAHL, IPA and The Cochrane Library. 
Additional search strategy information is available in the attached PDF document (link provided below).
 
Types of study to be included
All studies, irrespective of their design, will be included.
 
Condition or domain being studied
Metabolic syndrome screening, management and prevention, in which there is pharmacist involvement, and
the impact of the pharmacists' input. 
 
Participants/population









Comparisons of the impact of the interventions with or without pharmacist input, if the data is available. 
All studies will be included whether or not there is a control group.
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Context
Pharmacists’ input into the screening, management or prevention of metabolic syndrome, in diverse settings
and involving a range of modalities.
 
Main outcome(s)
Assessment of the impact of pharmacists’ input on the screening, management and prevention of metabolic
syndrome.
The outcomes are likely to be diverse and may include the following: comparisons of different models of
pharmacist input in MetS, descriptions of the process of development of the models, and the clinical and




Data extraction (selection and coding)
Two reviewers will independently review the titles and abstracts of the studies identified in the searches, and
the full texts of articles identified as being potentially eligible for inclusion will again be reviewed by two
reviewers independently, and decisions made regarding inclusion/exclusion. Any disagreements over the
eligibility of articles will be resolved by consultation with a third reviewer, and the included and excluded
studies will be documented as per PRISMA guidelines.
Data will then be extracted from the studies selected for inclusion using a customised data extraction form
which will be developed before the data extraction process begins. It is expected to include: study title, date,
country, duration, population characteristics, mode of the interventions, study design, methodology, the
primary and secondary outcomes, subgroup analysis and any other findings which address the study
objectives. 
 
Risk of bias (quality) assessment
The quality of the eligible studies will be critically appraised and assessed using standardised quality
assessment tools appropriate for the type of study, as follows:
Randomised controlled trials: the Cochrane bias assessment tool.
Observational studies (case-control and cohort studies): the STROBE (STrengthening the Reporting of
OBservational studies in Epidemiology) checklist.
Qualitative studies: the COREQ (COnsolidated criteria for REporting Qualitative research) bias assessment
tool.
Bias will be assessed by two reviewers independently, with any disagreements be resolved by discussion
with a third party. 
 
Strategy for data synthesis
A descriptive synthesis of the results from the included studies will be undertaken, which will allow for an
analysis of the evidence regarding the impact of pharmacist input into the screening, prevention and
management of MetS, the available pharmacist models of care, and the clinical outcomes in relation to the
MetS. 
A narrative description and tabulation will be presented for each study, and comparisons and contrasts within
and between studies in terms of populations, settings, methods, interventions, outcomes, subgroup analyses
or post hoc analyses, facilitators and barriers will also be made. 
 
Analysis of subgroups or subsets
Subgroup analyses will be carried out to explore the reported roles of pharmacists across different countries
and geographical regions. 
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Data from qualitative and quantitative studies will be aggregated and described using a narrative approach.
 
Contact details for further information
Rana Moustafa Al Adawi
rahmed4@hamad.qa
 
Organisational affiliation of the review
Hamad Medical Corporation




Review team members and their organisational affiliations
Dr Rana Al Adawi. Hamad Medical Corporation
Dr Antonella Tonna. Robert Gordon University
Professor Derek Stewert. Robert Gordon University
Dr Cristin Rayan. Trinity College
Dr Mohsen Eledrisi. Hamad Medical Corporation
Dr Hani Abdelaziz. Hamad Medical Corporation
 
Type and method of review
Intervention, Prevention, Systematic review
 






















Subject index terms status
Subject indexing assigned by CRD
 
Subject index terms
Community Pharmacy Services; Delivery of Health Care; Disease Management; Humans; Mass Screening;
Metabolic Syndrome; Pharmaceutical Services; Pharmacies; Pharmacists; Primary Prevention; Professional
Role
 
Date of registration in PROSPERO
07 March 2018
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Date of first submission
04 March 2018
 
Stage of review at time of this submission
The review has not started
 
Stage Started Completed
Preliminary searches No No
Piloting of the study selection process No No
Formal screening of search results against eligibility criteria No No
Data extraction No No
Risk of bias (quality) assessment No No
Data analysis No No
The record owner confirms that the information they have supplied for this submission is accurate and
complete and they understand that deliberate provision of inaccurate information or omission of data may be
construed as scientific misconduct.
The record owner confirms that they will update the status of the review when it is completed and will add
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